Drugmakers Avoided Scaling AI in Manufacturing
Regulatory hurdles and quality concerns slowed adoption of automation in clinical and commercial production.
Updated on Oct. 6, 2026 in Artificial Intelligence
Live Poll
Do you trust artificial intelligence to manage sensitive production processes without human oversight?
A 2026 report revealed that more than 90% of drugmakers have not yet scaled artificial intelligence applications within regulated manufacturing environments. Only 1% of surveyed organizations have implemented AI across most or all of their production workflows.
Why it matters
The biopharma sector prioritizes model accuracy and transparency, leading firms to favor administrative and drug discovery tasks over high-stakes manufacturing where quality validation is stringent. Manufacturing leaders currently struggle to provide the interpretable model outputs required by regulatory bodies.
While only 1% of firms have scaled AI in manufacturing, 56% utilize it for administrative workflows and 45% for drug discovery. The data highlights a significant gap between early-stage research utility and the rigorous validation required for large-scale production.
The players
CRB
An engineering and architecture firm specializing in the design of life sciences facilities and pharmaceutical manufacturing systems.
FDA
The federal agency responsible for protecting public health through the regulation of food, pharmaceuticals, and medical devices.
Purolea Cosmetics Lab
A laboratory firm targeted by regulators for failing to maintain human oversight of AI-generated production outputs.
The details
Manufacturing relies on high levels of precision that current AI models struggle to maintain in regulated settings, with nearly half of professionals citing quality and accuracy concerns. FDA oversight reflects these risks, as seen in an April 2026 warning letter to Purolea Cosmetics Lab that mandated human review of all AI-generated output. This requirement forces companies to maintain human-in-the-loop oversight to ensure that machine learning processes meet established safety standards.
Timeline
April 2026: FDA issued a warning letter regarding AI usage.
2026: CRB published the Horizons: Life Sciences report.
Next three years: 31% of respondents plan to use AI in manufacturing.
The Tech Race
The adoption of AI in manufacturing lags significantly behind administrative and drug discovery applications. The sector follows a trajectory constrained by strict regulatory oversight, where the burden of proof for model reliability dictates the speed of facility-level implementation.
The current landscape indicates that consumers will not see AI-driven efficiency gains in drug production for years, as most firms lack formal rollout plans. The industry is currently shifting toward human-augmented systems rather than fully automated production lines.
The takeaway
The gap between AI potential and regulated implementation remains wide, primarily due to the stringent accuracy demands of commercial drug production. Industry professionals should monitor future FDA guidance, as regulatory mandates for human-led review of model output will likely remain a standard constraint.
What happens next
Watch for the next wave of investment, as 31% of surveyed professionals intend to integrate AI into their manufacturing pipelines within the next three years.
Further reading
For broader trends in enterprise model implementation, see our coverage of Artificial Intelligence.
Source note: This article includes information reported by Pharma.
Live Poll
Do you trust artificial intelligence to manage sensitive production processes without human oversight?
